NCT03500380
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult), Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known central nervous system metastases
https://ClinicalTrials.gov/show/NCT03500380